Of 50 outpatients with nonpsychotic, nonmelancholic, anxious depression,
the 24 patients taking isocarboxazid had better scores on all outcome
measures than the 26 patients taking placebo. Differences on several
variables reached statistical significance by weeks 4-6.
Abstract Teaser